Gossamer Bio Q1 Earnings Call Highlights
Key Points - Gossamer Bio is still targeting a September 2026 NDA submission for seralutinib in pulmonary arterial hypertension, with a June FDA pre-NDA meeting set to help shape the filing. Management said approval could potentially follow in the third quarter of 2027 if